Experience

Magmatic Bio

• Austria
• Mining
• 1 - 100 Employee

• Founder

  • Jun 2022 - Present

  What if we could construct molecules that can separate metals no matter how similar they behave with precision no matter how small its concentration is? That's exactly what I'm working on right now. What if we could construct molecules that can separate metals no matter how similar they behave with precision no matter how small its concentration is? That's exactly what I'm working on right now.



XPol.org

• Zurich, Switzerland

• Chief Network Architect, Finance Partner

  • Apr 2021 - Present

  Xpol.org is a Deeptech venture builder for energy storage and conversion at the intersection of bioinorganic chemistry, structural biology and material science. We actively seek applied scientific breakthroughs through our network of academic researchers and translate them into deep tech start-ups. Our conviction is that fungal, microbial and arachneal life holds the key to energy efficiency in conversion and storage. Xpol.org is a Deeptech venture builder for energy storage and conversion at the intersection of bioinorganic chemistry, structural biology and material science. We actively seek applied scientific breakthroughs through our network of academic researchers and translate them into deep tech start-ups. Our conviction is that fungal, microbial and arachneal life holds the key to energy efficiency in conversion and storage.



AMSilk GmbH | Biotech Materials

• Germany
• Biotechnology Research
• 1 - 100 Employee

• Corporate Finance Partner

  • May 2020 - Jun 2021

  Fundraising to $29m Series C Round with strategic partners Novo Holding and Cargill. Fundraising to $29m Series C Round with strategic partners Novo Holding and Cargill.



AFFiRiS AG

• Austria
• Biotechnology
• 1 - 100 Employee

• Chief Executive Officer

  • Jul 2014 - Mar 2019

  AFFiRiS develops vaccines for the prevention and treatment of chronic illnesses. Our Vision is delay onset or prevent diseases such as Atherosclerosis, Parkinson's, Alzheimer's and Huntington's disease with our Peptide based conjugate vaccines based on our AFFITOME proprietary technology. We aim to target at populations which are either by their genetic predisposition or by defined and validated biomarkers at risk of developing chronic illness. AFFiRiS develops vaccines for the prevention and treatment of chronic illnesses. Our Vision is delay onset or prevent diseases such as Atherosclerosis, Parkinson's, Alzheimer's and Huntington's disease with our Peptide based conjugate vaccines based on our AFFITOME proprietary technology. We aim to target at populations which are either by their genetic predisposition or by defined and validated biomarkers at risk of developing chronic illness.



Rothschild & Co

• France
• Financial Services
• 700 & Above Employee

• Managing Director

  • Aug 2007 - Dec 2013

  Head of Pharmaceutical Investment Banking Head of Pharmaceutical Investment Banking



HSBC

• United Kingdom
• Financial Services
• 700 & Above Employee

• Head of Healthcare Investment Banking

  • Jun 2005 - Jul 2007



Merrill Lynch

• United States
• Financial Services
• 700 & Above Employee

• Director

  • Jun 1997 - Aug 2005

  Healthcare Investment Banking, some of the most fabulous transactions in a team which was like home Healthcare Investment Banking, some of the most fabulous transactions in a team which was like home



Deutsche Bank

• Germany
• Financial Services
• 700 & Above Employee

• Associate

  • 1995 - 1997